Clinical Significance of Heterozygosity for Mutations of the SLC12A3 Gene Coding for the Thiazide Sensitive Na-Cl Cotransporter

NCT02035046 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2017-01-16

No results posted yet for this study

Summary

Gitelman syndrome is a salt wasting tubulopathy caused by mutations in the SLC12A3 gene coding for the thiazide sensitive sodium chloride cotransporter. This disease mimics the chronic treatment with thiazide diuretics and is characterized by renal hypokalemia, low to normal blood pressure, hypocalciuria and hypomagnesemia. The purpose of this study is to determine whether the heterozygous carriers present the metabolic risks and/or the benefits of this disease.

Conditions

  • Heterozygous Carriers of Gitelman Syndrome

Interventions

PROCEDURE

Samplings of blood

PROCEDURE

Sampling of urine

PROCEDURE

Measure of the blood pressure

PROCEDURE

glycemia test

Sponsors & Collaborators

  • Ministry of Health, France

    collaborator OTHER_GOV
  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Rosa Vargas-Poussou, MD, PhD · Departement of Genetics. Assistance Publique Hôpitaux de Paris,Hôpital Européen Georges Pompidou.

  • Anne Blanchard, MD, PhD · Clinical Research Center. Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou. Paris, France

  • Marie Essig, MD, PhD · Departement of Nephrology. Centre Hospitalier Universitaire. Limoges, France

  • Jean Philippe Haymann, MD, PhD · Department of Functional Investigations. Assistance Publique Hôpitaux de Paris, Hôpital Tenon, Paris, France

  • Ivan Tack, MD, PhD · Department of Functional Investigations. Centre Hospitalier Universitaire, Hôpital de Rangueil. Toulouse, France

  • Laurence DUBOURG, MD, PhD · Department of Functional Investigations. Hospices Civils de Lyon, Hôpital Edouard Herriot. Lyon, France

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02035046 on ClinicalTrials.gov